EPI-321 twelve-month FSHD data
Epicrispr reported six-month EPI-321 data in October 2026 and targeted twelve-month data from all participants for H2 2027. The AAV-delivered epigenetic therapy targets DUX4 expression in FSHD.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Study enrollment and six-month reporting are already complete. Cohort size/missing-data policy must be pinned rather than changed after listing.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
Company target: H2 2027; exact presentation date unconfirmed
Company context
Company-authored LinkedIn About explicitly states Type: Privately Held and links epicrispr.com. Opened and checked October 31, 2026. This is an undated company self-report, not independent registry proof. The company news index additionally reports its August 2026 Series C close, but financing alone is not used as ownership proof.
Potential outcome market
Will Epicrispr publicly present twelve-month data from all treated participants in NCT06907875 by the market deadline?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.